Edesa Biotech Stock Total Debt
| EDSA Stock | USD 2.38 0.06 2.46% |
Edesa Biotech fundamentals help investors to digest information that contributes to Edesa Biotech's financial success or failures. It also enables traders to predict the movement of Edesa Stock. The fundamental analysis module provides a way to measure Edesa Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Edesa Biotech stock.
Edesa |
Edesa Biotech Company Total Debt Analysis
Edesa Biotech's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Edesa Biotech Total Debt | 19.87 K |
Most of Edesa Biotech's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Edesa Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, Edesa Biotech has a Total Debt of 19.87 K. This is 100.0% lower than that of the Biotechnology sector and 99.99% lower than that of the Health Care industry. The total debt for all United States stocks is 100.0% higher than that of the company.
Edesa Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Edesa Biotech's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Edesa Biotech could also be used in its relative valuation, which is a method of valuing Edesa Biotech by comparing valuation metrics of similar companies.Edesa Biotech is currently under evaluation in total debt category among its peers.
Edesa Fundamentals
| Return On Equity | -1.51 | ||||
| Return On Asset | -0.74 | ||||
| Current Valuation | 15.73 M | ||||
| Shares Outstanding | 6.99 M | ||||
| Shares Owned By Insiders | 9.29 % | ||||
| Shares Owned By Institutions | 25.98 % | ||||
| Number Of Shares Shorted | 852.08 K | ||||
| Price To Earning | (3.96) X | ||||
| Price To Book | 13.06 X | ||||
| Price To Sales | 120,478 X | ||||
| Gross Profit | 311.2 K | ||||
| EBITDA | (6.13 M) | ||||
| Net Income | (6.17 M) | ||||
| Cash And Equivalents | 12.81 M | ||||
| Cash Per Share | 0.83 X | ||||
| Total Debt | 19.87 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 2.68 X | ||||
| Book Value Per Share | 0.37 X | ||||
| Cash Flow From Operations | (4.89 M) | ||||
| Short Ratio | 0.02 X | ||||
| Earnings Per Share | (1.87) X | ||||
| Target Price | 19.0 | ||||
| Number Of Employees | 16 | ||||
| Beta | 0.77 | ||||
| Market Capitalization | 17.06 M | ||||
| Total Asset | 3.81 M | ||||
| Retained Earnings | (58.59 M) | ||||
| Working Capital | (157.21 K) | ||||
| Current Asset | 6.92 M | ||||
| Current Liabilities | 581.49 K | ||||
| Net Asset | 3.81 M |
About Edesa Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Edesa Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Edesa Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Edesa Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Edesa Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Edesa Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Edesa Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Edesa Biotech Stock:Check out Edesa Biotech Piotroski F Score and Edesa Biotech Altman Z Score analysis. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. If investors know Edesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edesa Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Edesa Biotech is measured differently than its book value, which is the value of Edesa that is recorded on the company's balance sheet. Investors also form their own opinion of Edesa Biotech's value that differs from its market value or its book value, called intrinsic value, which is Edesa Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edesa Biotech's market value can be influenced by many factors that don't directly affect Edesa Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edesa Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Edesa Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edesa Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.